Payment overview · 2025
General Payments
$317.77
12 reported records · 7 companies
Healthcare provider profile · identity verified
Sarah Walker Hampton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DONALSONVILLE, GA · NPI 1609872217
Verified facts
What the public records show
CMS Open Payments records show Sarah Walker Hampton, MD received $317.77 in general payments during 2025 across 12 reported records.
Ferring Pharmaceuticals Inc. accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.64 | 34.5% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $71.57 | 22.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.28 | 17.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.90 | 7.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.42 | 7.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.36 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.60 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.77 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ADSTILADRIN Normalized: adstiladrin |
Biological | Ferring Pharmaceuticals Inc. | $109.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 552 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 418 | 73 |
| Potassium Chloride | Potassium Chloride | 418 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 78 |
| Gabapentin | Gabapentin | 344 | 73 |
| Famotidine | Famotidine | 340 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 56 |
| Losartan Potassium | Losartan Potassium | 274 | 58 |
| Prednisone | Prednisone | 254 | 110 |
| Alprazolam | Alprazolam | 239 | 37 |
| Furosemide | Furosemide | 238 | 62 |
| Tramadol Hcl | Tramadol Hcl | 224 | 50 |
| Eliquis | Apixaban | 220 | 23 |
| Omeprazole | Omeprazole | 209 | 48 |
| Allopurinol | Allopurinol | 192 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 21 |
| Glimepiride | Glimepiride | 169 | 34 |
| Lisinopril | Lisinopril | 158 | 36 |
| Mounjaro | Tirzepatide | 157 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 153 | 17 |
| Metformin Hcl | Metformin Hcl | 153 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 30 |
| Bumetanide | Bumetanide | 130 | 20 |
| Enalapril Maleate | Enalapril Maleate | 130 | 30 |
| Azithromycin | Azithromycin | 126 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 18 |
| Montelukast Sodium | Montelukast Sodium | 112 | 30 |
| Carvedilol | Carvedilol | 108 | 25 |
| Simvastatin | Simvastatin | 106 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 11 |
| Meloxicam | Meloxicam | 101 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | suppressed |
| Clonazepam | Clonazepam | 94 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 91 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 27 |
| Pregabalin | Pregabalin | 89 | 20 |
| Sertraline Hcl | Sertraline Hcl | 89 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 59 |
| Jardiance | Empagliflozin | 84 | 15 |
| Olanzapine | Olanzapine | 79 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 78 | 14 |
| Memantine Hcl | Memantine Hcl | 78 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 17 |
| Trazodone Hcl | Trazodone Hcl | 78 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 13 |
| Ezetimibe | Ezetimibe | 70 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 17 |
| Cefuroxime | Cefuroxime Axetil | 67 | 45 |
| Topiramate | Topiramate | 65 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 25 |
| Glipizide | Glipizide | 62 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 12 |
| Nifedipine Er | Nifedipine | 59 | 12 |
| Synthroid | Levothyroxine Sodium | 59 | 11 |
| Mirtazapine | Mirtazapine | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Lorazepam | Lorazepam | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Fluconazole | Fluconazole | 53 | 29 |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 34 |
| Valsartan | Valsartan | 49 | 12 |
| Methotrexate | Methotrexate Sodium | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Ozempic | Semaglutide | 47 | 11 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 32 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Primidone | Primidone | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Risperidone | Risperidone | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 37 | 20 |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 12 |
| Digoxin | Digoxin | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Linzess | Linaclotide | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 28 | 19 |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Estradiol | Estradiol | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 23 | suppressed |
| Etodolac | Etodolac | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 19 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.77 · 12 records | Ferring Pharmaceuticals Inc. | ADSTILADRIN, AFFINITY, AIRSUPRA, Auvelity, Ozempic, PURAPLY WOUND MATRIX, QUTENZA, Rybelsus, TRELEGY ELLIPTA, VIA MATRIX, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error